Abstract
It has long been known that the major irreversible toxicity of aminoglycosides is ototoxicity. Among them, streptomycin and gentamicin are primarily vestibulotoxic, whereas amikacin, neomycin, dihydrosterptomycin, and kanamicin are primarily cochleotoxic. Cochlear damage can produce permanent hearing loss, and damage to the vestibular apparatus results in dizziness, ataxia, and/or nystagmus. Aminoglycosides appear to generate free radicals within the inner ear, with subsequent permanent damage to sensory cells and neurons, resulting in permanent hearing loss. Two mutations in the mitochondrial 12S ribosomal RNA gene have been previously reported to predispose carriers to aminoglycosideinduced ototoxicity. As aminoglycosides are indispensable agents both in the treatment of infections and Meniere ’ s disease, a great effort has been made to develop strategies to prevent aminoglycoside ototoxicity. Anti-free radical agents, such as salicylate, have been shown to attenuate the ototoxic effects of aminoglycosides. In this paper, incidence, predisposition, mechanism, and prevention of aminoglycoside-induced ototoxicity is discussed in the light of literature data.
Keywords: Aminoglycosides, ototoxicity
Current Pharmaceutical Design
Title: Aminoglycoside-Induced Ototoxicity
Volume: 13 Issue: 1
Author(s): Erol Selimoglu
Affiliation:
Keywords: Aminoglycosides, ototoxicity
Abstract: It has long been known that the major irreversible toxicity of aminoglycosides is ototoxicity. Among them, streptomycin and gentamicin are primarily vestibulotoxic, whereas amikacin, neomycin, dihydrosterptomycin, and kanamicin are primarily cochleotoxic. Cochlear damage can produce permanent hearing loss, and damage to the vestibular apparatus results in dizziness, ataxia, and/or nystagmus. Aminoglycosides appear to generate free radicals within the inner ear, with subsequent permanent damage to sensory cells and neurons, resulting in permanent hearing loss. Two mutations in the mitochondrial 12S ribosomal RNA gene have been previously reported to predispose carriers to aminoglycosideinduced ototoxicity. As aminoglycosides are indispensable agents both in the treatment of infections and Meniere ’ s disease, a great effort has been made to develop strategies to prevent aminoglycoside ototoxicity. Anti-free radical agents, such as salicylate, have been shown to attenuate the ototoxic effects of aminoglycosides. In this paper, incidence, predisposition, mechanism, and prevention of aminoglycoside-induced ototoxicity is discussed in the light of literature data.
Export Options
About this article
Cite this article as:
Selimoglu Erol, Aminoglycoside-Induced Ototoxicity, Current Pharmaceutical Design 2007; 13 (1) . https://dx.doi.org/10.2174/138161207779313731
DOI https://dx.doi.org/10.2174/138161207779313731 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Concurrent Use of Antiretrovirals and Anticonvulsants in Human Immunodeficiency Virus (HIV) Seropositive Patients
Current Pharmaceutical Design DNA Methylation in the Pathogenesis of Systemic Lupus Erythematosus
Current Pharmacogenomics Headache in Multiple Sclerosis - Pharmacological Aspects
Current Pharmaceutical Design Highly Organized Nanostructures for Brain Drug Delivery - New Hope or Just a Fad?
CNS & Neurological Disorders - Drug Targets Viruses and Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets New Drugs for Epidural Analgesia
Current Drug Targets Methoxychalcones: Effect of Methoxyl Group on the Antifungal, Antibacterial and Antiproliferative Activities
Medicinal Chemistry Synthesis of the Alzheimer Drug Posiphen into its Primary Metabolic Products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their Inhibition of Amyloid Precursor Protein, α -Synuclein Synthesis, Interleukin-1β Release, and Cholinergic Action.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Intranasal Fluorescent Nanocrystals for Longitudinal <i>In Vivo</i> Evaluation of Cerebral Microlesions
Pharmaceutical Nanotechnology State of the Art of Nanobiotechnology Applications in Neglected Diseases
Current Nanoscience Synthesis of New α-Amino Phosphonates Containing 3-Amino-4(3H) Quinazolinone Moiety as Anticancer and Antimicrobial Agents: DFT, NBO, and Vibrational Studies
Current Organic Synthesis Amyloidosis and Auto-Inflammatory Syndromes
Current Drug Targets - Inflammation & Allergy Antibiotic Treatment in Native Valve Infective Endocarditis
Infectious Disorders - Drug Targets Targeted Oncolytic Herpes Simplex Viruses for Aggressive Cancers
Current Pharmaceutical Biotechnology Coccidioidomycosis Involving the Cranium: A Case Report and Review of Current Literature
Infectious Disorders - Drug Targets Laboratory Diagnosis and Therapy of Invasive Fungal Infections
Current Drug Targets Synthesis of Imidazo[1,2-b]pyridazine Comprised Piperazine, Morpholine Derivatives as Potent Antimycobacterial Agents with In Vivo Locomotor Activity
Anti-Infective Agents Effective Separation and Simultaneous Detection of Ceftriaxone Sodium and Levofloxacin in Human Urine by Capillary Zone Electrophoresis
Current Analytical Chemistry Colored Representation of Brain Gray Scale MRI Images to Potentially Underscore the Variability and Sensitivity of Images
Current Medical Imaging Novel Kynurenic Acid Analogues in the Treatment of Migraine and Neurodegenerative Disorders: Preclinical Studies and Pharmaceutical Design
Current Pharmaceutical Design